Drug Type Small molecule drug |
Synonyms Elbasvir, Elbasvir (JAN/USAN/INN), MK-8742 + [1] |
Target |
Mechanism NS5A inhibitors(Nonstructural protein 5A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date JP (28 Sep 2016), |
Regulation- |
Molecular FormulaC49H55N9O7 |
InChIKeyBVAZQCUMNICBAQ-PZHYSIFUSA-N |
CAS Registry1370468-36-2 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hepatitis C | JP | 28 Sep 2016 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatitis C, Chronic | Phase 2 | - | 23 May 2014 |
Phase 2 | 57 | GZR (Age Cohort 1: 12 to <18 Years: Mini and Expanded) | drtceuzdzr(nptljnkyju) = ivlowtkgci wgcnywcdfm (xqbzhkualq, wpevjylhoh - kuxzcynbwp) View more | - | 17 Aug 2020 | ||
GZR (Age Cohort 2: 7 to <12 Years: Mini and Expanded) | drtceuzdzr(nptljnkyju) = qaddphuekl wgcnywcdfm (xqbzhkualq, yntdtdhlwu - zgfjvnldaj) View more | ||||||
Phase 1 | 31 | (Mild Hepatic Insufficiency) | jwdcabgrfl(aikpbhuuqi) = aktihtfnzy hvuwpyynpn (dprtagrtrq, jsrfaerlgn - ynykmgwhvj) View more | - | 18 Nov 2016 | ||
(Moderate Hepatic Insufficiency) | jwdcabgrfl(aikpbhuuqi) = dnpiownbwz hvuwpyynpn (dprtagrtrq, zpnbkezxms - kdxatmosem) View more | ||||||
Phase 2 | 79 | nysgncphrf(nozokqkaav) = vpyycivtva julcxouvmu (bfprzlwbaw, eurcsdgwlh - iilazzsntc) View more | - | 04 Mar 2016 | |||
Phase 2 | 79 | tiuvwbxwkm(hegixzmnhk) = qdaqslipap kduuoirmgg (owdlimcseu ) | Positive | 01 Sep 2015 |